Other News

ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator

ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients. In addition, the company announced submission of an IDE supplement to the US FDA for a pivotal study of its Paradise System for the treatment of hypertension, […]

MicroPort(TM)’s Firehawk(TM) Drug Eluting Stent Achieves Primary Endpoint and Shows Very Promising Results From TARGET All-Comers Clinical Trial

PARIS, May 23, 2018 /PRNewswire/ — Today MicroPort Scientific Corporation (HKSE: 0853) (“MicroPort™”) announced primary endpoint data at 12 months and QCA angiography data at 13 months from its TARGET All-Comers (TARGET AC) trial. The results of the TARGET AC trial demonstrated that vessels treated with the Firehawk sirolimus drug eluting stent […]

MyoKardia Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 21, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,750,000 shares of its common stock. All shares of […]

HeartFlow Analysis Demonstrates Highest Diagnostic Performance for Detecting Heart Disease Compared to Other Non-Invasive Tests

PARIS, May 22, 2018 (GLOBE NEWSWIRE) — HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive cardiac tests. Additionally, data from […]

FAST Study Demonstrates High Diagnostic Accuracy of CAAS vFFR and Received USA 510(k) Market Clearance

MAASTRICHT, Netherlands, May 22, 2018 /PRNewswire/ — A highly innovative software, developed by Pie Medical Imaging – PMI – B.V. (Esaote Group) will be presented at EuroPCR 2018, the world-leading course in interventional cardiovascular medicine, held in Paris, Palais des Congrès (France) between 22 – 25 May 2018. This software – called CAAS vFFR (Cardiovascular Angiographic Analysis Systems for vessel […]

Nobles Medical Technologies II Showcases Noblestitch™ PFO Closure At EuroPCR

PARIS, May 22, 2018 /PRNewswire/ — NMT2  announces it will be featured at the 2018 EUROPCR Congress in Paris, France.  The annual assembly, which again takes place at the Palace de Congress in Paris from May 22-25, 2018, is the worldwide gathering for in-depth scientific presentations, new innovations, training and reports of clinical data results in the […]

A New Approach for Normalizing Cardiac Arrythmias

WASHINGTON, May 21, 2018 /PRNewswire/ — An article published in Experimental Biology and Medicine (Volume 243, Issue 8, May, 2018) identifies a new approach for treating cardiac arrythmias (http://journals.sagepub.com/doi/full/10.1177/1535370218769420). The study, led by Dr. Congxin Huang, in the Cardiovascular Research Institute at Wuhan University in China, reports that treatment with a β-receptor antagonist abolishes cardiac arrythmias in […]

AngioMune™ Universal Donor T Regulatory Cell Product Effectively Reverses Cardiac Damage in Animal Models of Heart Disease

SAN DIEGO, May 21, 2018 /PRNewswire/ — Viera BioScience announced today positive data demonstrating that its AngioMune™ T Regulatory Cell based product successfully reduced cardiac damage and stimulated production of new blood vessels in animals that were induced to undergo a heart attack.  The use of T regulatory cells for angiogenesis is […]

Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve

PARIS, May 22, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced 30-day data demonstrating that treatment with the Edwards SAPIEN 3 valve in more than 450 commercial centers around the U.S. show consistently positive patient outcomes. The […]